Our Q&As are emailed in our Saturday Morning Report, find the answer to this question below.
Hi James Engaged in discovery, development, manufacturing and marketing of pharmaceutical products, NVO has two business segments - diabetes care and biopharmaceuticals. Of particular interest is the growth NVO's diabetes and obesity products in the USA. Is this a stock you have considered for the international portfolio?
Hi Steve,
It is a stock that has come across my radar but unfortunately we have not invested. We scan for large cap growth in the US and NVO US has very good sales & earnings momentum this year which is driving a strong re-rate higher in the share price.
Overnight (13th April) they upgraded again, Citi who has a buy on the stock I think summed up the news the best…. the new guidance is “pretty awesome” and it is “impressed” by the growth Novo is delivering, albeit this was widely anticipated. The group is still offering “materially” better growth and returns than pharma industry peers and earnings visibility beyond 2035.
While clearly a great result and strong trend in the stock, the risk/reward looks a lot better into ~10% pullbacks, which happen fairly regularly, particularly after widely anticipated good news has been delivered, the next catalyst can be some way off.
Take a free trial.
No payment details required.
Forgot password? Request a One Time Password or reset your password
One Time Password
Check your email for an email from [email protected]
Subject: Your OTP for Account Access
This email will have a code you can use as your One Time Password for instant access
A link to create a new password will be sent to the email address you have registered to your account.
Hi, this is only available to members. Join today and access the latest views on the latest developments from a professional money manager.
Our Smart Phone App will give you access to much of our content and notifications. Download for free today.
